Armata Pharmaceuticals (NYSEAMERICAN:ARMP) Announces Quarterly Earnings Results

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) posted its quarterly earnings data on Wednesday. The company reported ($0.27) earnings per share for the quarter, beating the consensus estimate of ($0.44) by $0.17, FiscalAI reports. The firm had revenue of $2.51 million for the quarter, compared to the consensus estimate of $0.40 million.

Armata Pharmaceuticals Stock Performance

ARMP stock opened at $4.68 on Thursday. The firm has a market capitalization of $171.99 million, a price-to-earnings ratio of -0.61 and a beta of 1.30. The firm has a 50 day moving average price of $5.70 and a 200-day moving average price of $8.14. Armata Pharmaceuticals has a 52-week low of $2.39 and a 52-week high of $16.34.

Analyst Ratings Changes

Separately, Zacks Research upgraded Armata Pharmaceuticals to a “hold” rating in a research report on Monday, May 18th. Two research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $15.00.

Hedge Funds Weigh In On Armata Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in shares of Armata Pharmaceuticals by 5.1% during the fourth quarter. Geode Capital Management LLC now owns 109,888 shares of the company’s stock valued at $690,000 after purchasing an additional 5,342 shares in the last quarter. State Street Corp boosted its position in Armata Pharmaceuticals by 26.1% in the fourth quarter. State Street Corp now owns 50,800 shares of the company’s stock worth $319,000 after purchasing an additional 10,500 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of Armata Pharmaceuticals during the 4th quarter valued at about $108,000. Millennium Management LLC purchased a new stake in shares of Armata Pharmaceuticals during the 4th quarter valued at about $164,000. Finally, Renaissance Technologies LLC lifted its stake in shares of Armata Pharmaceuticals by 65.9% in the 4th quarter. Renaissance Technologies LLC now owns 68,496 shares of the company’s stock worth $430,000 after purchasing an additional 27,200 shares during the period. 3.57% of the stock is currently owned by institutional investors.

About Armata Pharmaceuticals

Armata Pharmaceuticals, Inc is a clinical-stage biotechnology company developing targeted bacteriophage therapies to address antibiotic-resistant bacterial infections. The company’s proprietary platform harnesses naturally occurring viruses that selectively infect and destroy bacterial pathogens, offering a novel approach to combating drug-resistant strains that pose significant challenges in hospital and community settings.

Armata’s pipeline includes phage-based candidates aimed at Pseudomonas aeruginosa, a common cause of hospital-acquired pneumonia and infections in cystic fibrosis patients, as well as Staphylococcus aureus and other priority pathogens.